| Supervised enhancer prediction with epigenetic pattern recognition and targeted validation A Sethi, M Gu, E Gumusgoz, L Chan, KK Yan, J Rozowsky, I Barozzi, ... Nature methods 17 (8), 807-814, 2020 | 72 | 2020 |
| Targeting Gys1 with AAV‐SaCas9 decreases pathogenic polyglucosan bodies and neuroinflammation in Adult Polyglucosan Body and Lafora disease mouse models E Gumusgoz, DR Guisso, S Kasiri, J Wu, M Dear, B Verhalen, S Nitschke, ... Neurotherapeutics 18 (2), 1414-1425, 2021 | 34 | 2021 |
| Lafora disease: current biology and therapeutic approaches S Mitra, E Gumusgoz, BA Minassian Revue neurologique 178 (4), 315-325, 2022 | 22 | 2022 |
| AAV-mediated artificial miRNA reduces pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and Lafora disease mouse models E Gumusgoz, S Kasiri, DR Guisso, J Wu, M Dear, B Verhalen, ... Neurotherapeutics 19 (3), 982-993, 2022 | 18 | 2022 |
| Brief report: identification of elite and viremic controllers from a large urban HIV ambulatory center in Kampala, Uganda A Kayongo, E Gonzalo-Gil, E Gümüsgöz, AJ Niwaha, F Semitala, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 79 (3), 394-398, 2018 | 16 | 2018 |
| Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy S Mitra, B Chen, P Wang, EE Chown, M Dear, DR Guisso, U Mariam, ... Disease models & mechanisms 16 (1), dmm049802, 2023 | 8 | 2023 |
| The pattern of brain metastasis in colorectal cancer: Efficacy of metastasectomy, chemotherapy. SY Goksu, MS Beg, A Sanjeevaiah, E Gumusgoz, D Hsieh, M Ozer, ... Journal of Clinical Oncology 39 (3_suppl), 40-40, 2021 | 2 | 2021 |
| CSTB gene replacement improves neuroinflammation, neurodegeneration and ataxia in murine type 1 progressive myoclonus epilepsy E Gumusgoz, S Kasiri, M Verma, J Wu, D Villarreal Acha, U Marriam, ... Gene Therapy 31 (5), 234-241, 2024 | 1 | 2024 |
| Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-optimized CSTB BA Minassian, E Gumusgoz US Patent 11,946,065, 2024 | | 2024 |
| Primary cutaneous SMARCA4‐deficient undifferentiated malignant neoplasm: A rare case report and literature review E Gumusgoz, BS Graham, GA Hosler Journal of Cutaneous Pathology 51 (4), 262-266, 2024 | | 2024 |
| CSTB gene replacement improves neuroinflammation, neurodegeneration and ataxia in murine Type 1 Progressive Myoclonus Epilepsy B Minassian, E Gumusgoz, S Kasiri, M Verma, J Wu, DV Acha, U Marriam, ... | | 2023 |
| Lafora progressive myoclonus-epilepsy: Laforin targets malin to glycogen. S Mitra, B Chen, P Wang, E Chown, M Dear, DR Guisso, U Mariam, J Wu, ... Disease Models & Mechanisms, dmm. 049802-dmm. 049802, 2022 | | 2022 |
| shRNA-Mediated Gene Therapy for the Treatment of Angelman Syndrome HR Kang, V Zaric, A Rahim, SP DeVries, Y Ma, E Gumusgoz, B Minassian, ... MOLECULAR THERAPY 30 (4), 264-264, 2022 | | 2022 |
| shRNA-Mediated Gene Therapy for the Treatment of Prader-Willi Syndrome V Zaric, HR Kang, A Rahim, Y Ma, E Gumusgoz, B Minassian, SJ Gray, ... MOLECULAR THERAPY 30 (4), 89-89, 2022 | | 2022 |
| Targeting Gys1 with SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models E Gumusgoz, DR Guisso, S Kasiri, J Wu, B Verhalen, S Nitschke, S Mitra, ... MOLECULAR THERAPY 29 (4), 267-268, 2021 | | 2021 |
| AAV-mediated Gene Replacement Therapy is Beneficial in Unverricht-Lundborg Disease Mouse Model E Gumusgoz, S Kasiri, J Wu, M Dear, X Chen, B Minassian AMERICAN JOURNAL OF PATHOLOGY 191 (10 S), S2-S2, 2021 | | 2021 |
| RNAi Dependent Gys1 Knockdown Decreases Glycogen Inclusions in Lafora Disease Mouse Models E Gumusgoz, B Verhalen, M Dear, D Evans, BA Minassian MOLECULAR THERAPY 28 (4), 321-321, 2020 | | 2020 |
Berge MinassianProfessor, Pediatrics, University of Toronto, Sr. Scientist, Genetics and Genome Biology, Sick KidsVerified email at sickkids.ca
